Pancreatic Cancer Research

ResearcherUniversity of Occupational and Environmental Health JapanActive in the last 2 years

Masaru Harada

Matched on ORCID iD 0000-0001-9891-3526; OpenAlex author ID A5080779719. Sources: OpenAlex.

Their work

Papers
6 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
5
Papers, trials and grants by year

2025: 2 papers · 2026: 4 papers

Papers 6

  1. Pretreatment geriatric nutritional risk index is associated with impaired treatment continuity and supportive care-relevant outcomes in unresectable pancreatic… Last author DOI 10.1007/s00520-026-11102-1↗
  2. Poorly differentiated clusters surpass tumor budding as novel prognostic factors in pancreatic cancer, especially in cases treated with neoadjuvant chemotherap… Co-author DOI 10.1186/s12876-026-04773-x↗
  3. Determinants of eligibility for second-line chemotherapy following gemcitabine plus nab-paclitaxel therapy in patients with unresectable pancreatic cancer: a r… Last author DOI 10.1186/s12876-026-05075-y↗
  4. Dynamic Nutritional Decline During the Diagnostic-to-Treatment Interval Is Associated with Treatment Resilience and Survival in Unresectable Pancreatic Ductal … Last author DOI 10.3390/nu18121998↗
  5. Long-chain fatty acyl CoA synthetase 4 expression in pancreatic cancer: a marker for malignant lesions and prognostic indicator for recurrence. Co-author DOI 10.1186/s13000-025-01659-6↗
  6. Autoimmune Acquired Factor V Deficiency in a Patient With Pancreatic Cancer Complicated by Cholangitis: A Rare Coagulopathy With a Favorable Course. Last author DOI 10.7759/cureus.87946↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tsuyoshi Ueda · 4 shared papers, 2025–2026 · strength 1.15
  2. Nobuhiko Shinohara · 3 shared papers, 2026 · strength 0.82
  3. Daiki Uchihara · 3 shared papers, 2025–2026 · strength 0.75
  4. Toshiyuki Nakayama · 2 shared papers, 2025–2026 · strength 0.49
  5. Yasuhisa Mori · 1 shared paper, 2026 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.